Contribution: Eureka/Eurostar
Cyclenium Pharma Inc
$350,000.00
EUREKA - Development of a Macrocyclic Inhibitor Against the Zika and Dengue Virus NS2B-NS3 Proteases
FY 2018-19 · 2018-06-01
Summary
This project is focused on discovering a candidate ready for entry into formal regulatory preclinical development for the prevention and treatment of flavivirus infections by blocking an enzyme vital to the viral lifecycle with a new type of chemical structure to address the significant worldwide threat posed by these pathogens.
Department
Program
Eureka/Eurostar
Recipient
Location
Montreal|Montréal, Quebec, Canada
Recipient Type
For-profit organization
Business Number
829528975
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2018-06-01 | 2018-19 | $350,000.00 |
| 1 | 2018-06-01 | 2018-19 | $350,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 91 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 91 jours.
Agreement End Date
2020-03-31
Agreement Number
907552
Agreement Start Date
2018-06-01
Agreement Title
EUREKA - Development of a Macrocyclic Inhibitor Against the Zika and Dengue Virus NS2B-NS3 Proteases
Agreement Title (French)
EUREKA - Développement d’un inhibiteur macrocyclique contre les protéases de virus Zika et Dengue NS2B-NS3
Agreement Type
Contribution
Agreement Value
$350,000.00
Amendment Date
2019-01-28
Amendment Number
1
Coverage
EUREKA is a leading facilitator of innovation, providing a proven platform for international R&D&I cooperation. | EUREKA est un facilitateur de premier plan en innovation, fournissant une plate-forme reconnu pour la coopération internationale en R & D & I.
Description
This project is focused on discovering a candidate ready for entry into formal regulatory preclinical development for the prevention and treatment of flavivirus infections by blocking an enzyme vital to the viral lifecycle with a new type of chemical structure to address the significant worldwide threat posed by these pathogens.
Description (French)
Ce projet est axé sur la découverte d’un candidat prêt pour une entrée en développement préclinique réglementaire officiel pour la prévention et le traitement des infections flavivirus en bloquant une enzyme essentiel au cycle de vie virale avec un nouveau type de structure chimique pour adresser l’importante menace posée dans le monde par ces agents pathogènes.
Expected Results
Eureka promotes and supports market-oriented international R&D&I project generation, and facilitates access to financing for companies involved in its projects. EUREKA’s strength lies in its well-established international network, connecting 41 full member countries from Europe and 4 associated member countries.
Expected Results (French)
Eureka promouvoit et soutient la génération de projets internationaux de R & D & I axés sur le marché et facilite l'accès au financement pour les entreprises impliquées dans ses projets. La force d'EUREKA réside dans son réseau international bien établi, qui relie 41 pays membres d'Europe et 4 pays membres associés.
Federal Riding
Saint-Laurent
Federal Riding (French)
Saint-Laurent
Federal Riding Number
24068
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Eureka/Eurostar
Program Name (French)
Eureka/Eurostar
Program Purpose
Eureka promotes and supports market-oriented international R&D&I project generation, and facilitates access to financing for companies involved in its projects. EUREKA’s strength lies in its well-established international network, connecting 41 full member countries from Europe and 4 associated member countries.
Program Purpose (French)
Eureka promouvoit et soutient la génération de projets internationaux de R & D & I axés sur le marché et facilite l'accès au financement pour les entreprises impliquées dans ses projets. La force d'EUREKA réside dans son réseau international bien établi, qui relie 41 pays membres d'Europe et 4 pays membres associés.
Recipient Business Number
829528975
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
Cyclenium Pharma Inc
Recipient Postal Code
H4S 1Z9
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2018-2019-Q1-907552
